May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
The Effect of Discontinuing Nasal Steroids on Intraocular Pressure in Patients with Glaucoma or Ocular Hypertension.
Author Affiliations & Notes
  • C.M. Bui
    Dept. of Ophthalmology & Visual Sciences, Vanderbilt University, Nashville, TN
  • K.M. Joos
    Dept. of Ophthalmology & Visual Sciences, Vanderbilt University, Nashville, TN
  • Footnotes
    Commercial Relationships  C.M. Bui, None; K.M. Joos, None.
  • Footnotes
    Support  Olive Lewellyn Glaucoma Research Fund
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 945. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.M. Bui, K.M. Joos; The Effect of Discontinuing Nasal Steroids on Intraocular Pressure in Patients with Glaucoma or Ocular Hypertension. . Invest. Ophthalmol. Vis. Sci. 2004;45(13):945.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Systemic steroids may elevate intraocular pressure (IOP), and nasal steroids are being prescribed more commonly for allergic rhinitis. We examined the effects of discontinuing nasal steroid sprays on IOP in patients with glaucoma or ocular hypertension (OHT). Methods: A retrospective chart review of glaucoma and OHT patients with elevated or suboptimal IOP while using nasal steroids was performed after approval by the Vanderbilt Institutional Review Board. The glaucoma diagnosis and the type of steroid nasal spray were noted for each patient. The average IOP for each pair of eyes was determined from each of the pre–steroid, steroid–usage, and post–steroid clinical examinations. Data were analyzed with a Friedman Repeated Measures ANOVA on Ranks, and Tukey Pairwise Multiple Comparison Procedure. Results:13 patients (12 glaucoma, 1 OHT) were identified with an elevation of IOP while using nasal steroids. No patient realized that the nasal sprays were steroids, and 2 patients were known systemic steroid–responders. The mean IOP for each pair of eyes were calculated from the pre–steroid (14.5+4.5 mmHg, range 9–23.5 mmHg), steroid–usage (17.5+5.2 mmHg, range 12–30 mmHg), and post–steroid (13.8+3.2 mmHg, range 9.5–20 mmHg) examinations. Twenty–one of the 26 eyes had a decreased IOP after discontinuation of the nasal steroids for a mean of 42±26 days. The mean percent decline of the averaged IOP of both eyes of each patient was 19+13% (range –4 to 47%). There was a significant difference in averaged IOP of both eyes among the 3 time points (p=0.002), with a significant increase between pre–steroid IOP and steroid–usage IOP (p<0.05), as well as a significant decrease between steroid–usage IOP and post–steroid IOP (p<0.05). There was no significant difference between pre–steroid IOP and post–steroid IOP (p>0.05). All patients were able to avoid or delay additional medical or surgical therapy. Conclusions: A clinically and statistically significant reduction in IOP may be achieved with discontinuation of steroid nasal spray in patients with glaucoma or OHT. Nasal steroids may contribute to IOP elevation and warrant inquiry about their usage in patients with glaucoma or OHT who may be unaware that their nasal spray is a steroid.

Keywords: intraocular pressure • drug toxicity/drug effects • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×